Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study

BACKGROUND: Shorter duration of infusion of monoclonal antibody treatments may reduce treatment burden and improve healthcare resource utilization. METHODS: This phase II study recruited Japanese patients with previously untreated CD20+ B-cell non-Hodgkin lymphoma. Patients received intravenous obin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohmachi, Ken, Ando, Kiyoshi, Kinoshita, Tomohiro, Kumagai, Kyoya, Hatake, Kiyohiko, Ishikawa, Takayuki, Teshima, Takanori, Kato, Koji, Izutsu, Koji, Ueda, Eisuke, Nakai, Kiyohiko, Kuriki, Hiroshi, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057540/
https://www.ncbi.nlm.nih.gov/pubmed/30060000
http://dx.doi.org/10.1093/jjco/hyy087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057540/
https://www.ncbi.nlm.nih.gov/pubmed/30060000
http://dx.doi.org/10.1093/jjco/hyy087

Ejemplares similares